NCT06846541Phase 3Active not recruiting

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-11Estimated

Enrollment · participants1680Estimated

Source updated2026-04-13Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-02-25 · 1 field changed

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Plaque Psoriasis; Psoriasis (PsO); Psoriasis; Moderate Psoriasis; Severe Psoriasis

Treatments or interventions studied

Open-Label EnvudeucitinibDrug
Blinded EnvudeucitinibDrug
PlaceboDrug

Primary outcomes · main study measures

measure: To assess the long-term safety and tolerability of ESK-001 throughout the duration of the study; description: Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); timeFrame: Approximately 4 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history